PCRX
Pacira BioSciences Inc

1,567
Mkt Cap
$986.48M
Volume
990,121.00
52W High
$27.64
52W Low
$19.84
PE Ratio
48.42
PCRX Fundamentals
Price
$21.60
Prev Close
$22.93
Open
$22.91
50D MA
$24.34
Beta
0.39
Avg. Volume
834,880.77
EPS (Annual)
-$2.15
P/B
1.28
Rev/Employee
$887,298.73
News
all
press releases
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Lauren Riker Sells 1,416 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 1,416 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an average price...
MarketBeat·7d ago
News Placeholder
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of "Hold" from Analysts
Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received a consensus rating of "Hold" from the seven research firms that are presently covering the firm, MarketBeat.com...
MarketBeat·10d ago
News Placeholder
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. DOMA Perpetual Capital...
PR Newswire·14d ago
News Placeholder
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc.
Simplify Asset Management Inc. lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 62.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned...
MarketBeat·14d ago
News Placeholder
Pacer Advisors Inc. Trims Position in Pacira BioSciences, Inc. $PCRX
Pacer Advisors Inc. decreased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 48.2% during the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·15d ago
News Placeholder
75,598 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The...
MarketBeat·18d ago
News Placeholder
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX
Assenagon Asset Management S.A. decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 51.9% in the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·23d ago
News Placeholder
5 Biotech Stocks to Watch for Potential Upside
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Zacks·27d ago
News Placeholder
EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX
EcoR1 Capital LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·1mo ago
<
1
2
...
>

Latest PCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.